This review focuses on novel aspects of the pathogenesis and advances in the therapy of multiple sclerosis (MS).
Introduction
Multiple sclerosis (MS) is considered a prototype inflammatory autoimmune disorder of the central nervous system (CNS). The etiology of this disease remains unknown, but an interplay between as-yet unidentified environmental factors and susceptibility genes appears most likely [1] . In consequence, these factors trigger a cascade, involving an inflammatory response within the CNS that results in demyelination, oligodendrocyte death, axonal damage, gliosis, and neurodegeneration. How these complex traits translate into the clinical presentation of the disease is a focus of ongoing research. A better understanding of the sequential evolution of the MS lesion, the development of clinical surrogate markers which would allow to define patients at higher risk, and increased awareness of the natural course of the disease will pave the way for an optimized treatment approach, utilizing currently approved and promising experimental drugs that may hopefully become available in the near future.
Insights from neuropathology
MS is considered a prototypic immune-mediated demyelinating disease of the CNS. Its morphological hallmarks are demyelination, inflammation, gliosis, and axonal damage [2, 3] , although heterogeneity of lesion pathology has been recognized. Four patterns of demyelination have been delineated [4] . Evidence gained from studies in animal models supports the concept of a strategic role of inflammation in the pathogenesis of MS [5] . Changes on magnetic resonance imaging (MRI) are indicative of blood-brain barrier disruption and CNS inflammation, correlate albeit moderately with clinical disability, and have apparently some predictive value for the course of the disease [6] . Immunomodulatory and immunosuppressive treatment strategies are proven to reduce relapse rate in MS patients [7] . Nevertheless, the reason why the immune system starts to attack the myelin sheath remains enigmatic. A recent publication by Barnett and Prineas [8 ] raises the possibility that the immune response in MS is secondary to a primary disease mechanism. The authors had the opportunity to analyze the brain of a young patient with relapsing-remitting MS (RRMS) who died within 17 h of the onset of a new symptomatic and fatal brainstem lesion. They observed extensive apoptosis of oligodendrocytes in a circumscribed small area and propose this as the initial event in lesion formation. Oligodendrocyte death would cause activation of resident microglia which phagocytose the debris. As part of the apoptotic pathway, activated complement is deposited on the myelin sheath, which within a few days appears vacuolated and attracts monocytes. This view of MS lesion formation proposes oligodendrocyte death as the primary cause of inflammation in the MS brain [9] . Leukocyte recruitment appears necessary for the removal of apoptotic membranes. The authors tried to confirm these observations in postmortem tissue from patients with early MS. In six out of 11 brains, a total of nine lesions also contained apoptotic oligodendrocytes, similar to the picture in the 14-year-old patient. On the other hand, in five other early MS cases and six patients with long-standing MS, such lesions were not depictable. Thus, this study underlines the heterogeneity of MS pathology. The pattern observed falls into the spectrum of a type 3 lesion according to Lucchinetti et al. [4] . Hence, there is clearly no need to completely change our view of the pathogenesis of MS. What causes oligodendrocyte death remains elusive; nevertheless, several possible pathways have been suggested, such as a virus infection of oligodendrocytes [4], hypoxic stress secondary to ischemia or an immune-mediated vasculitis [10] [11] [12] , or damage inflicted by cytokines and other immune mediators derived from activated microglia in what one might call friendly fire [13] [14] [15] [16] . Further studies are required to identify the specific factors governing lesion development of each subtype in MS. It remains to be seen from extended pathological studies whether the proposed four subtypes represent truly distinct patterns unique to the natural history of one individual's disease or a spectrum whose expression changes as the disease evolves during the patient's lifetime.
The possible contribution of CD8 þ T lymphocytes as effector cells mediating CNS damage is receiving increasing attention. These cells outnumber CD4 þ T cells in active plaques. Clonally expanded CD8 þ T cells have been found within MS lesions [17] as well as in the cerebrospinal fluid of MS patients [18] . In a recent study several identical expanded CD8 þ T cell clones could be retrieved from the brain and cerebrospinal fluid, and some from the blood of MS patients [19 ] . Interestingly, some of the brain-infiltrating CD8 þ T cell clones persisted for more than 5 years in the cerebrospinal fluid and/or blood, underlining the putative role of this cell population in perpetuating disease progression in MS. The detection of ectopic B-cell follicle-like structures with germinal centers in the cerebral meninges of two out of three patients with secondary progressive MS (SPMS) provides further clues in our understanding how humoral autoimmunity may be maintained in MS [25 ] . The meninges have been identified as possible sites of B-cell follicles in the animal model of experimental autoimmune encephalomyelitis as well [26] . In line with this finding, centroblasts, which are usually restricted to the lymph nodes, were detected in the cerebrospinal fluid [27] . Clonal accumulation of B cells and plasma cells in the cerebrospinal fluid has now been confirmed by singlecell PCR analysis [28, 29] . Clonal expansion of B lymphocytes can be detected in the cerebrospinal fluid of MS patients early in the disease process, emphasizing that specific stimulation of B-cell expansion in the CNS of MS patients occurs upstream in the immunopathogenetic cascade [29, 30] . Further studies will shed light on the role of various subpopulations of immunocompetent cells and their interplay in MS [31] .
Besides tissue destruction mediated by immunocompetent cells the lack of sufficient remyelination in MS is currently the focus of various research avenues. A recent report suggests that activation of oligodendrocyte progenitors, which are often present in abundance in the CNS, may be dependent on signals regulating the subcellular localization and/or activity of the basic helix-loop-helix transcription factor Olig1 [32 ] . Further insights into the molecular mechanisms of Olig1 function may have therapeutic implications given that this factor appears to propagate repair in the damaged MS brain [33] .
Natural history and prognostic factors
Natural-history studies provide crucial information in a number of ways. They form the basis for disease cost analysis, are relevant for the deployment of health-care resources, and play an indispensable role in the evaluation of efficacy in clinical trials. The natural history of MS has taught us that, over time, the majority of MS patients will exhibit progressive neurologic deterioration. Approximately 50% of patients diagnosed with MS will require the use of a cane to ambulate safely within 10 years, and 25 years from the time of diagnosis approximately 90% of MS patients have transitioned to a progressive form of the disease and sustain substantial clinical disability [34, 35] .
Pittock et al. [36 ,37 ] reassessed the 1991 Olmsted County MS prevalence cohort in 2001. Although survival was reduced and 30% of patients progressed clinically to needing a cane or wheelchair, or worse, over the 10-year follow-up period, most remained clinically stable or progressed only minimally [36 ] . The distribution of clinical disability in the Olmsted community remained stable for 10 years, suggesting that progression of disability for patients with RRMS or SPMS may be more favorable than reported previously. Once a certain clinical threshold of disability was reached, disease progression accelerated and the chance of developing significant disability rose [37 ] . Similarly, a study in northern Sweden obtaining data from an incidence cohort and a prevalence population suggests that the clinical course of MS may be slightly more benign than anticipated [38] . These observations, demonstrating that MS-related disability in the vast majority of individuals in a large community may change only modestly over 10 years, have a number of implications; moreover, an increased knowledge of the natural history of MS is important for the design and interpretation of randomized clinical trials [39] .
Time to accrued disability is apparently influenced strongly by the number of exacerbations during the early phases of the disease. Although clinically isolated syndromes (CISs) and RRMS are not classified as progressive forms of the disease, irreversible deficits can be established with each exacerbation and as such contribute to persistent clinical impairment and disability. Consequently, MS treatment should be initiated at the earliest possible time point to prevent accumulation of irreversible deficits. Based on the CHAMPS study the US Food and Drug Administration (FDA) approved the use of intramuscular interferon b-1a in patients with CISs and an MRI result suggestive of MS [40] . Decisions regarding the initiation of immunomodulatory therapy are influenced by concerns about adverse events and cost-benefit considerations at present. Thus, it is an ongoing debate how to define those patients that are at high risk of deterioration since early prognostic factors are lacking. The implementation of MRI has provided the means to stratify patients with higher risk of recurrent disease on the basis of the number and size of CNS lesions at their initial presentation [41] [42] [43] . A re-analysis of the optic neuritis trial revealed that the 10-year risk of MS following an initial episode of acute optic neuritis is significantly higher if there is a single brain MRI lesion. On the other hand, even when brain lesions were seen on MRI, only 40% of the patients developed clinical MS after 10 years [44] , and the clinical course was benign in most cases [45] . Along this line, a recent study confirms that patients with CISs presenting with optic neuritis have a smaller risk to convert to definite MS compared to other clinical topographies. Interestingly, in optic neuritis the baseline MRI was normal in nearly 50% [46] . These data underline the critical role of MRI and the need for better surrogate markers [47 ,48] , especially since MRI remains an expensive and logistically difficult examination to perform.
Recently, Berger and co-workers [49] provided evidence that the analysis of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with CISs might be a precise method to predict the early conversion to clinically definite MS. The authors could demonstrate that patients with anti-MOG and anti-MBP IgM antibodies experienced relapses more often and earlier than patients without these antibodies. The adjusted hazard ratio for the development of clinically definite MS was 76.5 among those seropositive patients, and 31.6 among those who were seropositive only for anti-MOG antibodies compared with the seronegative patients. These data, however, do not clarify the pathogenetic role of these antibodies. It remains to be established whether these myelin-reactive antibodies contribute to initial tissue damage, reflect a response to injury, or participate in a protective or remyelinating response to parenchymal destruction [50, 51] .
Another group was able to identify IgM antibodies against native glycosylated MOG in patients during the first demyelinating event and higher MOG-specific IgG antibodies in patients during relapses and in secondary chronic progressive forms by ELISA [52] . On the other hand, a third group, using a liquid-phase radiobinding assay, did not find any difference in the expression level of anti-MOG antibodies between MS patients and controls [53] . Because the solid-phase technique measures high-affinity antibodies, it is possible that the discrepancy is due to a low-affinity MOG binding of the IgM antibodies. Additional studies are needed to clarify the role of anti-MOG antibodies in MS. If the observations described by Berger et al. [49] could be confirmed by others, such a test would improve the quality of the diagnostic and prognostic information that can be used to guide treatment decision and strategies in the future. Currently ongoing trials in CIS patients will provide an excellent opportunity for such research.
Recently, a putative marker for neuromyelitis optica (Devic's disease; NMO-IgG) has been described [54 ] . This autoantibody, with a reported sensitivity of 73% and specificity of 91% for neuromyelitis optica, may be helpful in distinguishing neuromyelitis optica from MS. Moreover, these studies underline the critical role of the humoral immune response in inflammatory demyelination of the CNS.
The role of viral agents in the pathogenesis of MS has received support from recent epidemiological investigations. A number of studies demonstrated higher EpsteinBarr virus (EBV) antibody titers, higher virus load, and altered T-cell responses in MS patients [55] [56] [57] [58] . In a recent study, pediatric MS patients were analyzed for antibody titers against common viruses including EBV, cytomegalovirus, parvovirus B19, herpes simplex virus, and varicella zoster. Some 83% of pediatric MS patients compared with 42% of emergency-department and healthy controls had antibodies against EBV. A slightly higher reactivity was also noted for herpes simplex virus-1 but for none of the other pathogens [59] . The same group reported a reduced MS risk for individuals who had an extended exposure to an infant sibling during childhood. Interestingly, childhood exposure was associated with lower IgG antibody titers against EBV [60 ] . The authors conclude that late exposure to EBV may contribute to the development of MS. Other groups report a strong association with active infections with the neurotropic herpesvirus 6 (HHV-6) in a subset of patients with RRMS [61] . Such observations find support by a recent study in which HHV-6 was detected to a higher degree in oligodendrocytes within MS lesions and the normal appearing white matter when compared to control samples [62] .
Human endogenous retroviruses (HERVs) have also been implicated in the pathogenesis of MS. The functional consequences of HERV expression in glia cells were recently addressed by Antony and colleagues [63] . The authors reported that the HERV-W-encoded glycoprotein syncytin is upregulated in astrocytes within acute demyelinating MS lesions. Syncytin expression was cytotoxic for oligodendrocytes due to the release of redox reactants. These findings provide an explanation of how HERVs may mediate damage during neuroinflammation.
Immunomodulatory drugs and antibodies
In recent years, efficacy of interferon b and glatiramer acetate in the treatment of RRMS was demonstrated in a number of phase III trials. Moreover, interferon b was also shown to be efficacious in CISs in patients at risk from developing clinically definite MS as well as in secondary progressive forms of MS. Recently, a combined analysis of the European and North American [64] placebo-controlled studies with interferon b-1b in SPMS was published. These studies had yielded divergent results regarding their primary outcome of sustained disease progression. The aggregate data, subject to post-hoc analysis, suggest that both continuing relapse activity and pronounced disability progression might help to identify those patients with SPMS who are more likely to benefit from interferon therapy [65 ] .
Like many other proteins, interferons are potentially immunogenic, especially those produced by recombinant gene-expression technologies [66] . In several studies the appearance of neutralizing antibodies (NAbs) under treatment with interferon b has been documented. The reported frequencies and titers of NAbs vary considerably depending on administration, preparation, and the type of assay being used [67] . The presence of these NAbs may be associated with a reduction in clinical effectiveness [68] . In a recently published study Sorensen and co-workers [69] measured NAbs every 12 months for up to 60 months in 541 patients with MS under interferon therapy using an antiviral neutralization bioassay. Although the authors observed that patients during antibody-positive periods exhibited a significantly higher relapse rate compared to their antibody-negative periods, disease progression, as measured by the expanded disability status scale (EDSS), was not affected during this short observation period. It is of note, though, that for most of the b interferons no impact on disease progression has been documented in RRMS [7] . Moreover, the appearance of NAbs in the serum of patients treated with interferon may be transient [70] . Thus, further studies are warranted to evaluate the clinical implications of NAbs against interferons in greater detail.
Long-term treatment with glatiramer acetate also induces the development of serum antibodies [71] . One study revealed that after 12 months of therapy 33% of patients developed high and 14% low antibody titers and suggested that these antibodies block the effect of glatiramer acetate [72] . Other groups, however, could not detect any inhibitory effect of antibodies to glatiramer acetate, whether in vitro or in the animal model [73] . Thus further studies are needed to clarify this discrepancy.
Immunosuppressive therapies
The therapeutic approach to patients with SPMS and PPMS still remains challenging, especially since the degree of disability and the inflammatory activity as determined by the relapse rate can differ significantly between patients. Thus a treatment strategy must be designed on an individual basis (tailor-made) and carefully weigh the expected clinical benefit against the potential adverse effects of the chosen therapy. Cyclophosphamide is a cytotoxic alkylating agent exhibiting immunosuppressive effects that has been widely used in the treatment of neoplastic and autoimmune disorders. Besides its immunosuppressive effects cyclophosphamide has immunomodulatory properties [74] . Various unblinded studies suggested a positive treatment effect [75] . However, these benefits could not be confirmed in placebo-controlled trials [76] . Recent retrospective analyses of more than 500 MS patients found that cyclophosphamide was well-tolerated and suggested a better response in those patients that presented with a short progressive time course or with rapidly evolving SPMS [77, 78] . Another group assessed safety and tolerability of cyclophosphamide pulse therapy in progressive and very active MS by reviewing the files of 112 patients, of whom 81.8% judged this therapeutic regime as tolerable [79] . However, in the light of all given conflicting data and the known toxicity of the drug, the role of cyclophosphamide as a disease-modifying therapy in SPMS and progressive MS remains unclear and its application should be restricted to selected patients who have not responded to other, less toxic, alternatives.
Based primarily on the MIMS study and the FrenchBritish study mitoxantrone was approved for the treatment of SPMS and worsening RRMS [80, 81] . The potential for serious toxicity, especially cardiotoxicity and leukemia, however, must be taken into account when considering this therapy in individual patients [82] . Ghalie et al. [83] searched carefully for signs and symptoms of cardiac dysfunction in a retrospective chart analysis of 1378 patients. They noted congestive heart failure only in two patients after initiating mitoxantrone therapy and observed an incidence of cardiac heart failure in patients who received a mean cumulative dose of 60.5 mg/m 2 of <0.20%. Reviewing the French cohort of 802 patients, Edan and co-workers detected only one case with congestive heart failure (G. Edan, personal communication) . In a recent study using advanced sensitive, non-invasive, diagnostic tools, including functional, morphometric, and biochemical measurements, the authors did not detect any subclinical cardiotoxic effect of mitoxantrone up to a cumulative dose range of 100 mg/m 2 [84] . The additional application of cardioprotective drugs, such as dexrazoxane, as an add-on might be a promising approach to further reduce the cardiotoxic risk. In the animal model of MS, dexrazoxane even exhibited intrinsic synergistic immunosuppressive effects [85] .
Therapy-related acute leukemia (tAL) after mitoxantrone therapy faces more awareness, since several case reports have been published during recent years [86] [87] [88] [89] [90] [91] [92] [93] [94] . Two large retrospective series in 802 and 1378 MS patients revealed one case each of tAL and suggest that these figures are within or just above the range of the incidence in the general population [86, 95] . Edan, reviewing 4000 patient-years of exposure to mitoxantron, detected two cases of tAL, of which one was lethal (G. Edan, personal communication). Although tAL is rare, such observations stress the therapeutic dilemma between efficacy and toxicity of mitoxantrone therapy in MS and underline the need for continued pharmacovigilance to further evaluate the risk of tAL in patients with MS who have received mitoxantrone.
The immunological effects of mitoxantrone are not currently understood fully. Recent ex-vivo studies revealed that this drug is rapidly incorporated in circulating blood leukocytes and that mitoxantrone induces a pronounced suppression of proliferative responses as well as late/necrotic cell death with a preferential susceptibility of B cells [96 ] and antigen-presenting cells [97] .
Symptomatic therapy
Anecdotal reports have suggested that cannabinoids might have a beneficial effect on spasticity in MS. In a chronic animal model of MS, cannabinoid receptor activation ameliorated tremor as well as spasticity in affected mice [98] . The UK MS Research Group conducted a randomized, placebo-controlled trial in order to investigate the effect of oral cannabinoids as a symptomatic therapy for spasticity over 15 weeks in 667 patients with stable MS [99] . The therapeutic regime chosen failed to detect a significant treatment effect on spasticity associated with MS, as measured with the Ashworth scale. However, treatment with cannabinoids did result in some benefit in secondary outcome measures that assessed mobility and patients' perceptions of the effect of spasticity. Taken together, convincing evidence is still lacking that cannabinoids are effective in MS [100] . Intriguingly, evidence has been put forth that, at least in the animal model, cannabinoids might exhibit neuroprotective effects [101] .
Upcoming therapies
Probably the most exciting therapeutic approach at present is the specific targeting of adhesion molecules along the blood-brain barrier. The recently published phase II trial of natalizumab, a recombinant humanized monoclonal antibody against a4 integrins, for the treatment of MS revealed a significant reduction of the number of new gadolinium-enhancing lesions, the primary outcome, in both treatment arms (intravenous natalizumab at 3 and 6 mg/kg compared to placebo when administered every 28 days for 6 months) [102 ,103 ] . The relapse rate, a secondary outcome measure, was diminished significantly in both treatment arms as well.
Firm conclusions about the safety of a4 integrin inhibition, its long-term efficacy, and the potential of developing resistance to natalizumab cannot be drawn prior to completion and analysis of the two much larger phase III studies involving some 2000 patients, which are currently underway. Data analysis of the AFFIRM trial in which RRMS patients were randomized 2:1 to natalizumab or placebo after the first year during a 2-year study period revealed a significant reduction of the annualized relapse rate (66-68%), the number of new and enlarging T2 lesions, and gadolinium-enhancing lesions on MRI in the patient group receiving natalizumab. Reassuringly, the incidence of infections was overall not higher than in the placebo group. Anaphylactoid reactions were few and if at all occurred at the second infusion. These results convinced the FDA to license natalizumab for the treatment of patients with relapsing forms of MS in the USA (further details can be found at http://origin.www.fda.gov/cder/drug/infopage/ natalizumab/default.htm). In the acute MS relapse a single dose of natalizumab appears to be clinically ineffective [104 ] .
Accumulating experimental evidence suggests that 3-hydroxy-3-methyglutaryl CoA (HMG-CoA) reductase inhibitors, or statins, exhibit anti-inflammatory and neuroprotective properties which may be beneficial in the treatment of MS [105 -109] . Various experimental studies in the animal model as well as in-vitro observations in immunocompetent cells suggest that statins might act as immunomodulators on both T cells and monocytes [110, 111] . An effect on MRI parameters of oral simvastatin could be demonstrated in a small study involving 30 patients with RRMS. In this patient cohort the number and volume of gadolinium-enhancing lesions declined by 44 and 41%, respectively [112 ] . Further trials are underway to evaluate the clinical efficacy of statins in MS.
FTY720 represents a potent immunomodulator, acting on sphingosine 1-phosphate receptors, that induces an entrapment of lymphocytes in secondary lymphoid organs. Such an enhanced homing of T lymphocytes is dependent on the expression of various chemokines [113] ; on the other hand, recent reports indicate a direct impact of FTY720 on dendritic cells [114] . In experimental autoimmune encephalomyelitis (EAE) this drug was shown to be clinically effective [115, 116] . Whereas efficacy of this drug has been demonstrated in organ transplantation in human, its impact on immunemediated disorders, such as rheumatoid arthritis and MS, is currently under investigation. A phase II trial of FTY720 in relapsing forms of MS has just been completed; the results are expected to be published soon.
Minocycline represents another drug of great interest. It is increasingly being recognized to alleviate several neurological diseases [117 ] .
In a small open-label trial in 10 patients with RRMS an impressive effect was observable on the mean total number of enhancing lesions [118] , implicating inhibition of matrix metalloproteinases that allow penetration of the blood-brain barrier by autoreactive T lymphocytes. Minocycline may also deactivate microglial cells, attenuate apoptosis of neurons, and suppress free-radical production in the wake of a vigorous immune response. Recent in vitro data, however, suggest that the inhibition of macrophages/microglia cells may have a negative effect on oligodendrocytes, compromising their capacity to remyelinate [119] . Thus, further studies are required to delineate the positive and detrimental effects of minocycline-mediated immunomodulation.
A profound and long-lasting suppression of inflammation seems to be inducible by hematopoietic stem-cell transplantation. The clinical course of MS was claimed to be stabilized after autologous hematopoietic stem-cell transplantation, although controversial evidence has been presented [120] . Clearly, further trials are warranted to establish clinical efficacy and to judge risks and benefits of this rather aggressive therapeutic approach which is associated with 2-5% mortality.
Based on our increased understanding of the immunopathogenesis of MS various novel therapeutic approaches are currently pursued, either clinically or pre-clinically, such as targeting of the interleukin-2 receptor [121, 122] or of the tumor necrosis factor receptor [123] . In T cells, the voltage-gated Kv1.3 channel and the Ca 2þ -activated IKCa1 channel have been implicated to play a critical role in Ca 2þ signaling, activation, adhesion, and migration. Thus these channels could be considered as attractive targets for immunotherapy [124] [125] [126] . Similarly, sodium channels have gained further interest as potential targets. The Nav1.6 sodium channel has been co-localized together with the sodium-calcium exchanger, along extensive regions of degenerating axons in EAE [127] and in MS [128] . This raises the possibility that sodiumchannel blockade may attenuate the inflammatory response and protect axons in neuroinflammatory disorders, as demonstrated in EAE [129] . Interestingly, inflammatory mediators can upregulate the expression of various sodium channels in macrophages, in microglial cells, and on axons. Nevertheless, despite the converging evidence for a protective effect of sodium-channel blockers in neuroinflammatory disorders, important questions remain to be answered [130] .
Current trials in MS are reviewed by Killestein and Polman in this issue of Current Opinion in Neurology in greater detail [131] . The huge plethora of therapeutic approaches appears promising; nevertheless, further advances in MS therapy will depend on our growing understanding of the pathogenesis of this disease [132 ] .
Similarly, increasing efforts are being undertaken to promote remyelination and axonal regeneration in an attempt to achieve repair of tissue damage and recovery of function [133] . As an example, thyroid hormone has been shown to enhance remyelination in the animal model EAE when administered during the acute phase of the disease [134] . It still remains unclear why oligodendrocytes, present in the CNS, fail to remyelinate sufficiently. Interestingly, repeated CNS demyelination does not necessarily cause depletion of oligodendrocyte precursor cells and failure of remyelination [135] . Such studies are helpful to understanding mechanisms of myelination within the CNS; however, their translation into MS therapy clearly awaits further extensive research, which might take many years to come to fruition. In this context, stem cell research, utilizing both embryonic and adult stem cells, opens new avenues to promote tissue repair in the damaged CNS [136, 137] . The dangers of prematurely pushing laboratory stem cell research into clinical practice have been outlined recently [138 ] .
Conclusion
Currently available therapeutic options in fighting MS remain limited but several new approaches are currently under development or being evaluated in clinical trials [139] , and may eventually enlarge our therapeutic armamentarium. Immunomodulatory therapy should be initiated as early as possible in patients at risk. New serological surrogate markers might aid in the recognition of such patients. Apparently, disease heterogeneity is broad, as we learn from neuropathological observations. In-vivo attributes and markers of disease patterns should be identified and developed. Their availability would allow stratification of patients in therapeutic subgroups and render tailor-made treatments feasible. Neuroprotective and repair-promoting strategies require further development. In this elegant study, using complementarity-determining region 3 spectratyping, the authors were able to identify several identical, expanded CD8 þ T cell clones in the brain, cerebrospinal fluid, and blood of two MS patients. Some of the brain-infiltrating CD8 þ cell clones persisted for more than 5 years in the cerebrospinal fluid and/or blood, potentially contributing to disease progression. 
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